Type of antibody:
Releasable fluorochromes, Primary antibodies, Recombinant antibodies
Alternative names:
PDCD1, PD1, SLEB2, hPD-1, hPD-l, hSLE1

Specifications for CD279 (PD-1) Antibody, anti-human, REAdye_lease™


Clone REAL531 is an antibody fragment derived from the full CD279 (PD-1) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL531 recognizes the human CD279 antigen, also known as PD-1 (programmed death-1) or PD1. CD279 is a 55 kDa transmembrane protein belonging to the CD28/CTLA-4 family. It is expressed on T cells, B cells, NK cells, activated myeloid cells, and dendritic cells. CD279 is not expressed on naive T cells but induced after activation and expressed on late, differentiated T cells. The ligands PD-L1 (CD274, also known as B7-H1) and PD-L2 (CD273, also known as B7-DC) belong to the B7 immunglobulin superfamily. PD-1 and its ligands mediate inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathology.
PD-1 is used as a marker for angioimmunoblastic lymphoma.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675).

Alternative names

PDCD1, PD1, SLEB2, hPD-1, hPD-l, hSLE1

Detailed product information

Technical specifications

Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable fluorochromes, Primary antibodies, Recombinant antibodies
AntigenCD279 (PD1)
Alternative names of antigenPDCD1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
Distribution of antigenB cells, monocytes, T cells, dendritic cells, myeloid cells, tumor cells, thymocytes, other, spleen, tonsil

References for CD279 (PD-1) Antibody, anti-human, REAdye_lease™


  1. Serriari, N.-E. et al. (2010) B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J. Immunol. 185: 3140-3148
  2. Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19: 813-824
  3. Fife, B. T. et al. (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. N. Y. Acad. Sci. 1217: 45-59
  4. Keir, M. E. et al. (2008) PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704

Seems like you are coming from USA!
Do you want to visit our website in your country?